主要文件

查看所有文档

S0758

磺胺苯吡唑

Name: 磺胺苯吡唑
Brand: SIGMA

≥98%, CYP2C9 inhibitor, powder

别名:

4-氨基-N-(1-苯基-1H-吡唑-5-基)苯磺酰胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₅H₁₄N₄O₂S

化学文摘社编号:

526-08-9

分子量:

314.36

NACRES:

NA.77

PubChem Substance ID:

24278198

UNSPSC Code:

12352204

EC Number:

208-384-3

MDL number:

MFCD00057226

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

磺胺苯吡唑, ≥98%

Quality Level

100

assay

≥98%

form

powder

solubility

ethanol: 25 mg/mL, clear, colorless to yellow

storage temp.

2-8°C

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3

InChI

1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

InChI key

QWCJHSGMANYXCW-UHFFFAOYSA-N

Gene Information

human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)

说明

Application

磺胺苯吡唑已用作定量分析红景天提取物对细胞色素P450 2C9(cyp2c9)抑制作用的阳性对照。也用作内皮细胞和微粒体制品中的细胞色素P450 2C9 (cyp2c9)抑制剂。

Biochem/physiol Actions

抗细菌。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸（氧化应激和AP-1活化增加）的促炎症和致动脉粥样硬化作用。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸（氧化应激和AP-1活化增加）的促炎症和致动脉粥样硬化作用。抑制缓激肽诱导的tPA释放。

Still not finding the right product?

Explore all of our products under 磺胺苯吡唑

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

0000508715

0000436070

0000368519

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform

Moraes CB, et al.

SLAS discovery, 24(3), 346-361 (2019)

Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.

Zhiping Jin et al.

Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)

Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments

KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin.

Vienna E Brunt et al.

The Journal of physiology, 590(15), 3523-3534 (2012-06-08)

While it is accepted that NO is responsible for ∼60% of the plateau in cutaneous thermal hyperaemia, a large portion of the response remains unknown. We sought to determine whether the remaining ∼40% could be attributed to EDHF-mediated activation of

查看所有相关文献

全球贸易项目编号

货号	GTIN
S0758-500G	04061834743132
S0758-5X1G	04061833343364
S0758-1G	04061836830731
S0758-100G	04061834743118
S0758-25G	04061834743125